Long-acting HIV injection study in stable patients
Treatments studied
Part of Infections clinical trials.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with HIV
- Your viral load (HIV level in blood) has been undetectable (below 50 copies/mL) for at least 4 months, confirmed by at least two separate tests
- You are willing to sign a consent form and participate in the study
- No major exclusion criteria—you're welcome to ask if you qualify
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
This study looks at how people living with HIV feel (quality of life) and how well their virus is controlled after they finish a long-acting injectable treatment with cabotegravir and rilpivirine. It's a follow-up to see if this easier treatment helps people stay healthy and feel better.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.